OXERVATE® is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis (NK).

Prescribing Information

Site map

Home
About NK Etiologies Patient Presentation Clinical Presentation Diagnosis
Mechanism of Action MOA
Efficacy & Safety Study Design Study Results Clinical Outcomes Safety Profile
Dosing & Admin Dosing Administration The OXERVATE Kit Storage
Patient Access Dompé Connect to Care Patient Enrollment
Resources For Eye Care Professionals For Office Staff For Patients
Contact a Rep
Sign Up

Sign up for additional
resources and to
stay up to date
about OXERVATE®

For US healthcare professionals only.

Important Safety Information

WARNINGS AND PRECAUTIONS

Contact lenses, either therapeutic or corrective, should be removed before applying OXERVATE. Contact lenses may be reinserted 15 minutes after OXERVATE administration.

Eye Discomfort, such as eye pain, that can be mild to moderate can occur with OXERVATE. Patients should contact their health care provider if a more serious eye reaction occurs.

ADVERSE REACTIONS

The most common adverse reaction with OXERVATE (~16%) was eye pain. Other adverse reactions with OXERVATE (1% to 10%) included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

Please read the full Prescribing Information for OXERVATE.